Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

0.5120 -0.0280 (-5.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,010
Open 0.5242
Bid (Size) 0.5109 (1)
Ask (Size) 0.5400 (9)
Prev. Close 0.5400
Today's Range 0.5013 - 0.5700
52wk Range 0.3920 - 4.575
Shares Outstanding 402,116,835
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
ASLN stock results show that ASLAN Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-6.91%
-6.91%
1 Month
-27.88%
-27.88%
3 Month
-3.32%
-3.32%
6 Month
-60.62%
-60.62%
1 Year
-86.87%
-86.87%

More News

Read More
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
Via Talk Markets
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.